-
Je něco špatně v tomto záznamu ?
Fibroblast activation protein as a potential theranostic target in brain metastases of diverse solid tumours
M. Zubaľ, B. Výmolová, I. Matrasová, P. Výmola, J. Vepřková, M. Syrůček, R. Tomáš, Z. Vaníčková, E. Křepela, D. Konečná, P. Bušek, A. Šedo
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
- MeSH
- fibroblasty patologie MeSH
- individualizovaná medicína MeSH
- karcinom z renálních buněk * patologie MeSH
- kvalita života MeSH
- lidé MeSH
- membránové proteiny metabolismus MeSH
- nádorové mikroprostředí MeSH
- nádory ledvin * patologie MeSH
- nádory mozku * patologie MeSH
- serinové endopeptidasy metabolismus MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
Brain metastases are a very common and serious complication of oncological diseases. Despite the vast progress in multimodality treatment, brain metastases significantly decrease the quality of life and prognosis of patients. Therefore, identifying new targets in the microenvironment of brain metastases is desirable. Fibroblast activation protein (FAP) is a transmembrane serine protease typically expressed in tumour-associated stromal cells. Due to its characteristic presence in the tumour microenvironment, FAP represents an attractive theranostic target in oncology. However, there is little information on FAP expression in brain metastases. In this study, we quantified FAP expression in samples of brain metastases of various primary origin and characterised FAP-expressing cells. We have shown that FAP expression is significantly higher in brain metastases in comparison to non-tumorous brain tissues, both at the protein and enzymatic activity levels. FAP immunopositivity was localised in regions rich in collagen and containing blood vessels. We have further shown that FAP is predominantly confined to stromal cells expressing markers typical of cancer-associated fibroblasts (CAFs). We have also observed FAP immunopositivity on tumour cells in a portion of brain metastases, mainly originating from melanoma, lung, breast, and renal cancer, and sarcoma. There were no significant differences in the quantity of FAP protein, enzymatic activity, and FAP+ stromal cells among brain metastasis samples of various origins, suggesting that there is no association of FAP expression and/or presence of FAP+ stromal cells with the histological type of brain metastases. In summary, we are the first to establish the expression of FAP and characterise FAP-expressing cells in the microenvironment of brain metastases. The frequent upregulation of FAP and its presence on both stromal and tumour cells support the use of FAP as a promising theranostic target in brain metastases.
Department of Neurosurgery Na Homolce Hospital Prague Czech Republic
Department of Pathology Na Homolce Hospital Prague Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23016133
- 003
- CZ-PrNML
- 005
- 20240305122109.0
- 007
- ta
- 008
- 231013s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.pathol.2023.05.003 $2 doi
- 035 __
- $a (PubMed)37419841
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Zubaľ, Michal $u Laboratory of Cancer Cell Biology, Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic
- 245 10
- $a Fibroblast activation protein as a potential theranostic target in brain metastases of diverse solid tumours / $c M. Zubaľ, B. Výmolová, I. Matrasová, P. Výmola, J. Vepřková, M. Syrůček, R. Tomáš, Z. Vaníčková, E. Křepela, D. Konečná, P. Bušek, A. Šedo
- 520 9_
- $a Brain metastases are a very common and serious complication of oncological diseases. Despite the vast progress in multimodality treatment, brain metastases significantly decrease the quality of life and prognosis of patients. Therefore, identifying new targets in the microenvironment of brain metastases is desirable. Fibroblast activation protein (FAP) is a transmembrane serine protease typically expressed in tumour-associated stromal cells. Due to its characteristic presence in the tumour microenvironment, FAP represents an attractive theranostic target in oncology. However, there is little information on FAP expression in brain metastases. In this study, we quantified FAP expression in samples of brain metastases of various primary origin and characterised FAP-expressing cells. We have shown that FAP expression is significantly higher in brain metastases in comparison to non-tumorous brain tissues, both at the protein and enzymatic activity levels. FAP immunopositivity was localised in regions rich in collagen and containing blood vessels. We have further shown that FAP is predominantly confined to stromal cells expressing markers typical of cancer-associated fibroblasts (CAFs). We have also observed FAP immunopositivity on tumour cells in a portion of brain metastases, mainly originating from melanoma, lung, breast, and renal cancer, and sarcoma. There were no significant differences in the quantity of FAP protein, enzymatic activity, and FAP+ stromal cells among brain metastasis samples of various origins, suggesting that there is no association of FAP expression and/or presence of FAP+ stromal cells with the histological type of brain metastases. In summary, we are the first to establish the expression of FAP and characterise FAP-expressing cells in the microenvironment of brain metastases. The frequent upregulation of FAP and its presence on both stromal and tumour cells support the use of FAP as a promising theranostic target in brain metastases.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a membránové proteiny $x metabolismus $7 D008565
- 650 _2
- $a individualizovaná medicína $7 D057285
- 650 _2
- $a kvalita života $7 D011788
- 650 _2
- $a fibroblasty $x patologie $7 D005347
- 650 _2
- $a serinové endopeptidasy $x metabolismus $7 D012697
- 650 12
- $a karcinom z renálních buněk $x patologie $7 D002292
- 650 12
- $a nádory mozku $x patologie $7 D001932
- 650 12
- $a nádory ledvin $x patologie $7 D007680
- 650 _2
- $a nádorové mikroprostředí $7 D059016
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Výmolová, Barbora $u Laboratory of Cancer Cell Biology, Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic $7 xx0314709
- 700 1_
- $a Matrasová, Ivana $u Laboratory of Cancer Cell Biology, Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Výmola, Petr, $u Laboratory of Cancer Cell Biology, Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic $d 1994- $7 xx0314736
- 700 1_
- $a Vepřková, Jana $u Laboratory of Cancer Cell Biology, Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Syrůček, Martin $u Department of Pathology, Na Homolce Hospital, Prague, Czech Republic
- 700 1_
- $a Tomáš, Robert $u Department of Neurosurgery, Na Homolce Hospital, Prague, Czech Republic
- 700 1_
- $a Vaníčková, Zdislava $u Laboratory of Cancer Cell Biology, Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Křepela, Evžen $u Laboratory of Cancer Cell Biology, Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Konečná, Dora $u Laboratory of Cancer Cell Biology, Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic; Departments of Neurosurgery and Neurooncology, First Faculty of Medicine, Charles University and Military University Hospital, Prague, Czech Republic
- 700 1_
- $a Bušek, Petr $u Laboratory of Cancer Cell Biology, Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic. Electronic address: petr.busek2@lf1.cuni.cz
- 700 1_
- $a Šedo, Aleksi $u Laboratory of Cancer Cell Biology, Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic
- 773 0_
- $w MED00003708 $t Pathology $x 1465-3931 $g Roč. 55, č. 6 (2023), s. 806-817
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37419841 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20231013 $b ABA008
- 991 __
- $a 20240305122106 $b ABA008
- 999 __
- $a ok $b bmc $g 1999950 $s 1202495
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 55 $c 6 $d 806-817 $e 20230616 $i 1465-3931 $m Pathology $n Pathology $x MED00003708
- LZP __
- $a Pubmed-20231013